Healthcare Industry News: non-healing wounds
News Release - January 29, 2016
Human Regenerative Technologies, LLC (HRT) Announce WoundEx(R) Amniotic Membrane Products Receive Coverage From Novitas Solutions, Inc.Human Regenerative Technologies' WoundEx® amniotic membrane has been included in one of the country's largest Medicare Administrative Contractors coverage.
Novitas Solutions, Inc., (Novitas), the Medicare Administrative Contractor (MAC) for Jurisdiction H (Arkansas, Louisiana, Colorado, Louisiana, New Mexico, Maryland, Oklahoma, Texas) and Jurisdiction L (Delaware, DC, Mississippi, New Jersey, Pennsylvania) has updated its coverage policy (L35041) to include WoundEx® amniotic membrane (Q4163)
REDONDO BEACH, Calif., Jan. 29, 2016 -- (Healthcare Sales & Marketing Network) -- On January 28, 2016, Novitas Solutions, Inc., (Novitas), the Medicare Administrative Contractor (MAC) for Jurisdiction H (Arkansas, Louisiana, Colorado, Louisiana, New Mexico, Maryland, Oklahoma, Texas) and Jurisdiction L (Delaware, District of Columbia, Mississippi, New Jersey, Pennsylvania) has updated its coverage policy (L35041) to include WoundEx® amniotic membrane (Q4163). Novitas' Local Coverage Determination (LCD): Application of Bioengineered Skin Substitutes to Lower Extremity Chronic non-healing wounds (L35041) is available at www.cms.gov
"We are thrilled to have WoundEx® our Advance Wound Care Amniotic Product being covered by Novitas who is responsible for 13 States and approximately 11.3 million Medicare beneficiaries within its jurisdictions," commented Chis Sharp, CEO.
Novitas is one of the largest Medicare Administrative Contractors (MACs), which are responsible for processing Medicare claims across the 12 geographic jurisdictions in the U.S. Each MAC also issues local coverage determinations (LCDs) that specify which health care products and services are reimbursable through the Medicare Fee-for-Service program in the regions under its jurisdiction. Novitas is responsible for almost 25% of the total Medicare annual claims volume, with approximately 10 million fee-for-service beneficiaries, 1,700 Medicare hospitals and 220,000 physicians under its jurisdiction.
HRT is pleased that its WoundEx products have been recognized as a covered treatment for skin substitute applications. For questions regarding WoundEx® products, visit Skye Biologics at www.skyebiologics.com or contact HRT.
About Human Regenerative Technologies LLC (HRT) Harnessing the Regenerative Power of the Body®:
Human Regenerative Technologies, LLC (HRT®) is a regenerative biologics company, focused on advancing the understanding and development of human cellular and protein-based therapies through scientific and clinical application.
Human Regenerative Technologies (HRT) provides the highest quality and has developed the industry's most diverse line of active amniotic and placental based biologics utilizing our proprietary HydraTek® process to be applies in Wound Care, Foot & Ankle, Urology, Podiatry, OB/GYN, ENT, Dental, Oral and Maxillofacial, Orthopedics, Spine, Plastics and Cosmetics.
HRT's commercially available regenerative biologics successfully combine precise science and technology in the procurement, processing and delivery of innovative and novel active Extracellular Matrix (ECM) biologic products derived from human amniotic and placental tissues.
HRT continues to expand its national and international distribution network and private label opportunities with synergistic medical companies.
For more information, visit our website at www.humantissue.com or email: email@example.com
Any forward-looking statement is based on information available to Human Regenerative Technologies LLC as of the date of the statement. All written or oral forward-looking statements attributable to Human Regenerative Technologies LLC are qualified by this caution. HRT does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in HRT's expectations.
Source: Human Regenerative Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.